We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

4 hedge funds and large institutions have $29K invested in Northwest Biotherapeutics, Inc. Common stock in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more capital invested

Capital invested by funds: $29K → $29K ($0)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
1
Seelaus Asset Management
New Jersey
$13K – – –
WPP
2
Whalerock Point Partners
Rhode Island
$8K – – –
LDB
3
Lee, Danner & Bass
Tennessee
$5K – – –
MPI
4
Mairs & Power Inc
Minnesota
$3K – – –

NWBO Hedge Fund Activity: Q2 2018 in Review

4 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2018, worth a combined $29K — unchanged from a quarter earlier.

Fund positioning in NWBO was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 4 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $29K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2018, unchanged quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2018 and 0 closed out.

Based on aggregated 13F filings for Q2 2018.